Company intelligence / Profile preview

TeaRx

Ownership: Private
Development stage: Commercial

Overview

TeaRx has developed Tearexaban, an oral direct Factor Xa inhibitor for the prevention of venous thromboembolic events. A multicenter Phase 2 clinical trial compared Tearexaban to enoxaparin for VTE prevention following total knee replacement surgery. The program is pending further regulatory approval and commercialization in Russia and select countries under a license agreement with Roche[1][2][3].

Therapeutic areas: Cardiovascular
Modalities: Small molecule (specifically oral direct Factor Xa inhibitor)
Industry: Biotech

Drug pipeline

1 asset

tearxaban

Partnerships

F. Hoffmann-La Roche Ltd. (license agreement for development/commercialization of novel oral Factor Xa inhibitors in Russia and other countries)[3]

Beyond the preview

Go deeper on TeaRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeaRx.